UCB

Immunology + neurology

UCBJY · OTC · Belgium

Share price · UCBJY

$126.00-8.10 (-6.04%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when UCBJY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 31 Jul 2026+2.9%
  2. 30 Jul 2026-12.6%
  3. 15 Jun 2026-5.4%
  4. 28 Apr 2026-5.3%
  5. 21 Apr 2026-6.2%
  6. 26 Feb 2026-7.9%
  7. 12 Feb 2026+2.9%
  8. 6 Jan 2026+7.2%
  9. 31 Oct 2025-5.9%
  10. 28 Oct 2025-5.7%

Share of unusual movement by asset

For each asset, the share of UCBJY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
bimekizumab (Bimzelx)
events and moves
1814%
Fenfluramine (Fintepla)
events and moves
6shown from 8 days
cizutamig
events and moves
3shown from 8 days
CND261
events and moves
2shown from 8 days
Bepranemab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—76%

Assets

(16 total)
16Total Assets
10Approved
1Phase 3 / Filed
5Phase 1–2 / Early
14Diseases
Quick filter:
Showing 16 of 16 assets
Target & Modality
bimekizumab(Bimzelx)
Approved
IL-17A/FMonoclonal antibody
Psoriatic ArthritisPsoriasisHidradenitis Suppurativa
Approved
Synaptic vesicle glycoprotein 2A (SV2A)Small molecule
Epilepsy
Focal Onset Seizures
Approved
TNF-alphaAntibody fragment
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Crohn's Disease
Fenfluramine(Fintepla)
Approved
Serotonin 5-HT2 receptorsSmall molecule
EpilepsyRett SyndromeDevelopmental and Epileptic EncephalopathiesDravet SyndromeLennox-Gastaut Syndrome
Lacosamide(Vimpat)
Approved
Voltage-gated sodium channelsSmall molecule
Epilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures
Approved
Synaptic vesicle protein 2A (SV2A)Small molecule
Epilepsy
Focal Onset Seizures
Approved
Synaptic vesicle protein 2A (SV2A)Small molecule
Epilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures
Approved
GABA-A receptor · GABA-A receptor (benzodiazepine site)Small molecule
Epilepsy
Approved
dopamine precursorSmall molecule
Parkinson's Disease
rotigotine(Neupro)
Approved
Dopamine receptorsSmall molecule
Parkinson's Disease
Phase 3
GABA-A receptorSmall molecule
Epilepsy
Phase 2
Tau (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
Phase 2
IL-13, IL-17A, IL-17FMultispecific antibody
Atopic Dermatitis
Phase 2
D1 receptorSmall molecule
Parkinson's Disease
Phase 1
BCMA x CD3Multispecific antibody
Systemic Lupus Erythematosus

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
bimekizumab · BimzelxPhase 3Hidradenitis Suppurativa
Est. primary completion 2026-12-21 · NCT06921850 · CT.gov ↗
What to watch
2027 (5)
March 2027 (2)
bimekizumab · BimzelxPhase 3Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Est. primary completion 2027-03-09 · NCT06506916 · CT.gov ↗
What to watch
Staccato AlprazolamPhase 3Stereotypical Prolonged Seizures
Est. primary completion 2027-03-29 · NCT05077904 · CT.gov ↗
What to watch
May 2027 (1)
galvokimigPhase 2Atopic Dermatitis
Est. primary completion 2027-05-17 · NCT07277660 · CT.gov ↗
What to watch
November 2027 (1)
Fenfluramine · FinteplaPhase 3CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Est. primary completion 2027-11-08 · NCT05064878 · CT.gov ↗
What to watch
December 2027 (1)
bimekizumab · BimzelxPhase 3Palmoplantar Pustulosis
Est. primary completion 2027-12-27 · NCT07219420 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
bimekizumab · BimzelxPhase 3Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Est. primary completion 2028-04-12 · NCT06668181 · CT.gov ↗
What to watch
August 2028 (1)
bimekizumab · BimzelxPhase 3Moderate to Severe Plaque Psoriasis
Est. primary completion 2028-08-21 · NCT06425549 · CT.gov ↗
What to watch
November 2028 (1)
Staccato AlprazolamPhase 3Stereotypical Prolonged Seizures
Est. primary completion 2028-11-30 · NCT05076617 · CT.gov ↗
What to watch
2029 (4)
February 2029 (2)
Fenfluramine · FinteplaPhase 3Rett Syndrome
Est. primary completion 2029-02-06 · NCT07503444 · CT.gov ↗
What to watch
galvokimigPhase 2Non-cystic Fibrosis Bronchiectasis
Est. primary completion 2029-02-28 · NCT07720375 · CT.gov ↗
What to watch
June 2029 (1)
galvokimigPhase 2Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Est. primary completion 2029-06-29 · NCT07725939 · CT.gov ↗
What to watch
November 2029 (1)
BrivaracetamPhase 3Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Est. primary completion 2029-11-16 · NCT06315322 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
BrivaracetamPhase 3Epilepsy
Est. primary completion 2030-07-08 · NCT04715646 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 December 2025Topline resultFenfluramineGEMZ phase 3 study in CDKL5 deficiency disorder meets primary endpoint
27 June 2025Topline resultFenfluramineGEMZ Phase 3 (NCT05064878) in CDKL5 deficiency disorder met its primary and key secondary endpoints
UCB · Source ↗
20 November 2024ApprovalbimekizumabFDA approves BIMZELX for moderate-to-severe hidradenitis suppurativa
US, FDA · Source ↗
31 October 2024Topline resultBepranemabBepranemab Phase 2a TOGETHER (NCT04867616): primary endpoint (CDR-SB at Week 80) not met; secondary and subgroup signals
UCB S.A. · Source ↗

Financial reports

Quarterly & interim (5)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$3.8B$939M$1.9B—report ↗

UCB reported revenue of $3,809.22M, up 26.2% YoY, R&D spend of $939.47M, up 10.1% YoY, and cash and equivalents of $1,889.3M for H1 2025.

Figures only: this period's report disclosed no narrative text

View 4 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$3.0B$853M$458M—report ↗
2023-H1$2.8B$821M$497M—report ↗
2022-H1$3.2B$873M$538M—report ↗
2021-H1$3.3B$908M$676M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$8.8B———report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$6.7B$1.9B——report ↗
2023-FY$5.7B$1.8B——report ↗
2022-FY$5.8B$1.8B——report ↗
2021-FY$6.8B$1.9B$1.4B—report ↗

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 0.0M shares ($1.4M, 0.0% of shares outstanding).

#InstitutionSharesValue
1RHUMBLINE ADVISERS7,496$1.1M
2GAMMA Investing LLC1,696$256K
3PNC FINANCIAL SERVICES GROUP, INC.275$41K
4Salomon & Ludwin, LLC96$15K
5NBC SECURITIES, INC.10$1K
6Ancora Advisors LLC4$603
7HANTZ FINANCIAL SERVICES, INC.68$10